Clinical trial
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in…
NCT00217698 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00217698 |
|---|---|
| Title | Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gefitinib, gemcitabine hydrochloride |
| Enrollment | 63 |
| Start date | Nov 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 5, 2012 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: